Laser hair removal for hidradenitis suppurativa: evaluate disease response, not just hair loss

Hair-targeting laser treatment can be one component of care for confirmed hidradenitis suppurativa, but it is not interchangeable with a cosmetic hair-removal package or a cure for every stage of HS. The decision depends on the disease pattern, existing tunnels and scars, skin and hair characteristics, and the specific device evidence. Improvement in inflammatory lesions must be assessed separately from the amount of hair removed.¹²

Start with the part of HS the procedure is meant to address

HS is an inflammatory disease involving the follicular unit. A plan aimed at reducing follicular targets asks a different question from a procedure intended to remove established diseased tunnels. North American guidance discusses hair-targeting Nd:YAG treatment separately from CO2 laser excision and other surgical approaches.¹ The shared word “laser” does not make those procedures equivalent.

Ask the treating dermatologist to identify the purpose of the proposed treatment on a map of the involved area. Is the goal fewer inflammatory lesions, improvement in a defined region, management of established structural disease, or unwanted-hair reduction alongside medical care? Several goals can coexist, but each needs its own measure.

This article addresses an already assessed HS care decision. Recurrent bumps are not enough to establish that diagnosis. The PFB article covers a different, shaving-related problem and should not be used as an HS treatment plan.

What the small alexandrite trial adds

A 2024 randomized study enrolled 15 adults with bilateral HS and assessed 24 anatomical sites. One side received four monthly alexandrite treatments; the other served as the control. At week 24, the investigators reported HiSCR responses in 75% of treated sites versus 33.33% of control sites.² Those are site-level disease-response findings from a small trial, not the percentage of all future patients who will be cured.

The study included only a small number of people with advanced Hurley stage III disease. Its authors also cautioned against comparing the response directly with biologic-drug trials that enrolled different populations. Follow-up was limited; the result does not establish permanent remission or a universal session count.²

This is useful evidence to discuss, not a device advertisement. A practice should be able to explain whether its equipment, patient selection and outcome assessment resemble the study it cites. A wavelength name alone does not reproduce an entire trial.

Build a disease-response record

The table is a consultation framework, not a home scoring tool. Ask which clinical measure the practice uses and what degree of change would justify continuing, modifying or ending the course. The same method should be used at baseline and follow-up so that changes can be interpreted.

Read device evidence in its own category

The North American procedural guideline gave Nd:YAG a stronger evidence basis than several other hair-targeting approaches at the time of publication. More recent research adds alexandrite data; it does not retroactively turn every light-based service into the same treatment.¹²

A 2024 systematic review included 10 studies and 227 patients across different laser and light modalities.³ Pooling a literature can reveal a signal while still leaving uncertainty about the best approach for an individual. Differences in disease severity, device technique, concurrent treatments and follow-up matter when a clinic quotes a headline result.

Ask for the actual device and indication supporting the proposal. Clinical evidence for an off-label application should not be relabeled as FDA approval for HS. A device’s marketing status and the clinical study supporting a particular use are separate records.

Choose a team that can follow the disease between sessions

A cosmetic operator’s ability to reduce hair is not the whole service needed here. Identify who confirms the disease assessment, evaluates new or worsening symptoms, coordinates existing prescriptions, and decides whether another procedure is needed. Ask how the laser team shares observations with the clinician managing HS.

Do not change established medical treatment to make the laser course a stand-alone experiment. Instead, make concurrent care visible in the record. If several interventions change at once, the team should acknowledge that improvement cannot automatically be attributed to the laser alone.

Before paying, separate the clinical proposal from coverage. A diagnosed condition does not automatically make every procedure reimbursable; the insurance guide explains the documentation gates. Use provider discovery to begin a conversation, then verify the practice’s specific HS experience and medical follow-up capability directly.

The decisive question is “Which part of my assessed HS is this procedure intended to improve, and what would count as a meaningful response even if some hair remains?”